Last updated: August 25, 2026
FDA thyroid tablet recall 2026 involves one lot of Vitruvias Therapeutics Thyroid Tablets, USP 30 mg because testing confirmed that the medicine may be superpotent. The affected product contains animal derived thyroid hormones and is prescribed for hypothyroidism, also known as an underactive thyroid.[1]
The recall applies specifically to lot number 504950, NDC 69680-166-00, with an expiration date of September 30, 2026. It does not apply automatically to every thyroid medicine, every Vitruvias thyroid tablet strength or every animal derived thyroid product.[1,2]
Vitruvias Therapeutics announced the voluntary consumer level recall on August 21, 2026. The FDA published the company announcement on August 24, 2026. The affected lot was distributed nationwide in the United States through the company’s direct accounts between January 31, 2025, and September 30, 2025.[1]
Patients should check their medication promptly, but they should not stop thyroid treatment, skip doses, double doses or change to another thyroid product without speaking with their doctor or pharmacist. Abruptly stopping required thyroid replacement can allow hypothyroidism to return and may be particularly dangerous during pregnancy, infancy or after thyroid surgery.[1]
Which Thyroid Tablets Have Been Recalled?
Only one identified lot of Vitruvias Therapeutics Thyroid Tablets, USP 30 mg is included in the August 2026 recall. The product is a natural thyroid preparation derived from porcine thyroid glands and contains both levothyroxine, known as T4, and liothyronine, known as T3.[1,2]
Each labelled 30 mg tablet contains 19 micrograms of levothyroxine and 4.5 micrograms of liothyronine. The 30 mg designation refers to the weight of the thyroid preparation and should not be interpreted as 30 mg of levothyroxine or liothyronine.[2]
Recalled Thyroid Tablet Identification
| Recall information | Product details |
|---|---|
| Company | Vitruvias Therapeutics, Inc |
| Product | Thyroid Tablets, USP |
| Strength | 30 mg, equivalent to 1/2 grain |
| NDC | 69680-166-00 |
| Lot number | 504950 |
| Expiration date | September 30, 2026 |
| Bottle size | 100 tablets |
| Levothyroxine content on label | 19 micrograms per tablet |
| Liothyronine content on label | 4.5 micrograms per tablet |
| Tablet appearance | Round, pale brown or off white tablet |
| Tablet imprint | THY and 050 |
| Distribution area | Nationwide in the United States |
| First distribution date | January 31, 2025 |
| Last distribution date | September 30, 2025 |
| Units released | 3,655 |
| Units reported sold | 1,955 |
| Recall reason | Potential superpotency |
| Reported recall related adverse events | None reported as of the FDA announcement |
The FDA notice states that 3,655 units were released and 1,955 units were sold. Patients should not assume that an older prescription is unaffected simply because it was dispensed several months ago. The expiration date extends through September 30, 2026, so bottles or tablets from the recalled lot may still remain in homes, pharmacies, care facilities or travel medicine supplies.[1]
What Does Superpotent Thyroid Medicine Mean?
A superpotent medicine contains or delivers more active hormone than its intended specification. A patient taking the prescribed number of tablets may therefore receive more thyroid hormone than expected.
The FDA announcement does not publicly state how far above specification the recalled tablets tested. It confirms only that testing established the potential for superpotency.[1]
Thyroid hormone has a narrow therapeutic range. A dose that is too low may allow hypothyroidism symptoms to return, while a dose that is too high can produce thyrotoxicosis, which means excessive thyroid hormone activity in the body.[3,4]
The recalled medicine contains both T4 and T3. T3 acts more rapidly at body tissues and has a stronger biological effect per microgram than T4. This is one reason why symptoms, pulse rate and laboratory results must be interpreted by a clinician rather than by comparing the 30 mg tablet strength directly with a synthetic levothyroxine dose.[2]
Symptoms of Superpotent Thyroid Tablets
Excess thyroid hormone can accelerate metabolism and increase stimulation of the heart and nervous system. Possible symptoms include unexplained weight loss, heat intolerance, excessive sweating, nervousness, anxiety, irritability, hand tremor, insomnia, muscle weakness, fatigue, frequent bowel movements, diarrhoea and increased appetite.[1,4,5]
Some patients may first notice that their usual thyroid dose suddenly feels different. They may experience a racing heart, unusual restlessness, difficulty sleeping, shakiness or feeling excessively warm despite no change in weather or activity.
The FDA specifically warns about hypertension, chest pain, rapid heart rate and heart rhythm disturbances. A patient with atrial fibrillation, coronary artery disease, heart failure or another cardiovascular condition may experience greater risk from excessive thyroid hormone.[1,6]
Older adults may not always develop obvious tremor, sweating or nervousness. Their first sign may be weakness, breathlessness, unexplained weight loss, worsening angina, irregular heartbeat, confusion or reduced exercise tolerance.
Symptoms and Recommended Patient Response
| Symptom or situation | Possible significance | Recommended response |
|---|---|---|
| Mild heat intolerance, sweating, anxiety or insomnia | Possible excess thyroid hormone | Contact the prescribing clinician or pharmacist promptly and verify the lot |
| Tremor, diarrhoea, unexplained weight loss or muscle weakness | Possible developing thyrotoxicosis | Arrange medical assessment and ask whether thyroid blood tests are required |
| Persistent rapid heartbeat or irregular pulse | Possible cardiac effect of excess hormone | Obtain urgent medical advice on the same day |
| Chest pain, fainting or severe breathlessness | Possible serious cardiac complication | Seek emergency medical care immediately |
| Severe agitation, confusion, high fever, seizure or collapse | Possible severe toxicity | Call emergency services immediately |
| Pregnancy with exposure to the recalled lot | Increased maternal and fetal concern | Contact the obstetric and thyroid care team promptly |
| Infant or child taking the recalled product | Possible effect on growth and development | Contact the paediatric clinician immediately |
| No symptoms but confirmed lot 504950 | Exposure without recognised toxicity | Do not stop independently; arrange a replacement and clinical guidance |
The presence of symptoms does not prove that the recalled tablets are responsible. Anxiety, infection, anaemia, cardiac disease, menopause and several other conditions can cause similar symptoms. However, anyone taking lot 504950 should report new symptoms and disclose the recall exposure to the clinician.[1,4]
When Should You Seek Emergency Care?
Chest pain, severe shortness of breath, fainting, collapse, a sustained very rapid heartbeat or a clearly irregular heartbeat requires urgent assessment. Confusion, severe agitation, seizure, high fever or reduced consciousness may indicate serious toxicity and should not be monitored at home.[5]
A person with known heart disease should have a lower threshold for seeking medical care. Excess thyroid hormone can increase heart rate, oxygen demand and sensitivity to adrenaline. It may aggravate angina or precipitate a rhythm disturbance in a vulnerable patient.[1,6]
Do not drive yourself to hospital when experiencing chest pain, fainting, severe breathlessness or marked confusion. Use local emergency services.
What Should Patients Do With Lot 504950?
First, check the original manufacturer bottle, dispensing label, prescription paperwork or pharmacy application. Look for Vitruvias Therapeutics, Thyroid Tablets, USP 30 mg, NDC 69680-166-00, lot 504950 and expiration September 30, 2026.[1,2]
Many pharmacies transfer tablets from the manufacturer bottle into a standard pharmacy container. The patient label may show the medicine and strength without showing the original lot number. In this situation, contact the dispensing pharmacy and ask staff to check their purchasing, inventory and dispensing records.
Tell the pharmacist the date the prescription was dispensed, the prescription number, the 30 mg strength and the name of the manufacturer when available. Do not assume the product is affected based only on tablet colour, since medicines from different manufacturers may look similar.
Patients who are confirmed to have the recalled lot should contact their healthcare provider for further guidance and a replacement prescription. The company and FDA specifically state that patients should not discontinue the recalled medicine without contacting their healthcare provider.[1]
The replacement should come from an unaffected supply selected by the prescriber and pharmacist. Do not substitute a different strength, take half of a larger tablet, combine several smaller tablets or change between animal derived thyroid and synthetic levothyroxine without a professionally calculated plan.
Should You Stop Taking the Recalled Thyroid Tablets?
Do not stop on your own unless an emergency clinician directly instructs you to do so.
This advice can appear confusing because the product has been recalled. The reason is that untreated hypothyroidism can also cause harm. A patient may need an immediate replacement rather than an unplanned interruption in treatment.[1]
The safest response is to contact the prescriber and dispensing pharmacy as soon as possible. They can determine whether the product is actually from lot 504950, arrange an unaffected replacement and decide whether the next dose should be taken, withheld or modified.
Patients who have already stopped should tell their clinician how many doses were missed. They should not compensate by taking extra tablets.
Which Blood Tests May Be Needed?
Not every person who received the recalled lot will require the same investigations. The decision depends on the duration of exposure, symptoms, age, pregnancy status, heart history, thyroid diagnosis and previous laboratory results.
A clinician may consider thyroid stimulating hormone, free T4 and free T3. Because the recalled preparation contains both T4 and T3, measuring only one marker may not provide the full clinical picture. Pulse rate, blood pressure and an electrocardiogram may also be appropriate when palpitations, chest discomfort or an irregular heartbeat are present.[2,4]
Thyroid stimulating hormone can remain suppressed for some time after circulating thyroid hormone levels begin changing. Test results should therefore be interpreted together with symptoms, examination, dose history and the timing of the last tablet.
Patients should bring the medicine container or clear photographs of the front label, side label, lot number and expiration date to the appointment whenever possible.
Why Older Adults Face Greater Risk
The FDA identifies older adults as a population at greater risk from superpotent thyroid tablets, especially with prolonged exposure. Excess thyroid hormone can place stress on the cardiovascular system and contribute to rapid heartbeat or rhythm disturbances.[1]
A longitudinal study of 1,450 community dwelling adults found that thyroid hormone use was associated with a substantial risk of iatrogenic thyrotoxicosis, particularly among older women. The authors emphasised the recognised relationship between overtreatment, atrial fibrillation and reduced bone density.[6]
Older patients may also take several medicines, making it harder to distinguish thyroid toxicity from medication side effects or underlying disease. New weakness, breathlessness, unexplained weight loss, falls or changes in mental alertness should not be dismissed as normal ageing.
Advice for Pregnant Patients
Pregnant patients taking lot 504950 should contact their obstetric clinician and thyroid prescriber promptly. They should not stop thyroid hormone independently because adequate thyroid hormone is essential for maternal health and fetal development.
At the same time, excessive replacement during pregnancy is not harmless. The FDA notice states that overtreatment of hypothyroidism during pregnancy has been associated with a higher rate of maternal and fetal complications, including premature delivery and low birth weight.[1]
The clinician may review the exact product, dose, duration of exposure, thyroid stimulating hormone, free T4 and pregnancy specific targets before deciding on replacement.
Advice for Infants and Children
The FDA identifies infants as another population at increased risk. Excess thyroid hormone may negatively affect growth and development, particularly when exposure continues over time.[1]
Parents and caregivers should not attempt to alter an infant’s dose by crushing a different tablet strength or estimating a partial tablet without paediatric guidance. Contact the paediatrician, paediatric endocrinologist or dispensing pharmacy immediately for product verification and replacement instructions.
Changes in sleep, feeding, weight gain, sweating, irritability, diarrhoea or heart rate should be reported promptly.
Is This Recall Only in the United States?
The FDA announcement states that lot 504950 was distributed nationwide in the United States to Vitruvias Therapeutics direct accounts.[1]
The notice does not state that the product was officially distributed through regulated supply chains in the United Kingdom, Canada, Australia or Singapore. Patients in these countries should not assume that their locally supplied thyroid medicine is included.
However, people may obtain medicines while travelling, through international relatives, private importation or online sources. Anyone outside the United States who possesses Vitruvias Therapeutics Thyroid Tablets, USP 30 mg should check the lot number and contact a local pharmacist or medicine regulator when it matches lot 504950.
The recall does not apply automatically to levothyroxine products sold under different brand names in other countries.
Are All Natural Thyroid Medicines Being Recalled?
No. The August 2026 recall announcement identifies one lot of one strength from Vitruvias Therapeutics.[1]
It is nevertheless important to understand the wider regulatory context. The FDA states that animal derived thyroid medicines, sometimes called desiccated thyroid extract, are not FDA approved. These products are produced from dried animal thyroid glands, usually porcine glands, and contain both T4 and T3.[3]
The FDA has expressed concern that animal derived thyroid medicines may have inconsistent hormone levels because of their biological source and manufacturing complexity. An NDC number indicates that product information has been listed in the National Drug Code system. It does not by itself mean that the medicine has received FDA approval.[2,3]
Professional guidelines generally recommend synthetic levothyroxine as the preferred initial replacement treatment. Some patients nevertheless report better symptom control with a T3 containing approach. Any decision to use animal derived thyroid, levothyroxine alone or a carefully monitored combination should be individualised and supervised.[3]
Difference Between Superpotency and Subpotency
Superpotency means that a medicine may contain more active hormone than intended. It can lead to symptoms of excess thyroid hormone, such as heat intolerance, sweating, weight loss, tremor, palpitations, diarrhoea, high blood pressure or rhythm disturbance.
Subpotency means that a medicine may contain less active hormone than intended. It can allow hypothyroidism symptoms such as tiredness, cold intolerance, constipation, dry skin, hair loss, weight gain or slow heart rate to return.
The August 2026 Vitruvias recall concerns potential superpotency, not subpotency.[1]
Can the Recalled Tablets Cause Permanent Harm?
Many patients who receive excess thyroid hormone can recover after the source is corrected and hormone levels return to the intended range. The actual risk depends on how superpotent the tablets were, how many were taken, the duration of exposure and the patient’s medical condition.
The FDA announcement had received no reports of adverse events known to be associated with this recall at the time of publication.[1] This is reassuring, but it does not mean that symptoms should be ignored.
Prolonged overtreatment can increase concern about atrial fibrillation, cardiovascular strain and reduced bone density, particularly in older adults and postmenopausal women.[6]
Prompt identification, replacement of the affected medicine and appropriate monitoring can reduce the risk of continuing exposure.
How Ayurveda May Support Root Level Thyroid Recovery
Ayurveda should not be used to neutralise a superpotent tablet or delay the replacement of recalled medicine. The immediate priorities are product verification, medical assessment, thyroid testing when indicated and protection of the heart, pregnancy and child development.
Once the recall related risk has been addressed, a properly designed Ayurvedic programme may support deeper thyroid and metabolic recovery. Its role is not simply to give an energising herb for fatigue. A rational approach evaluates why the patient developed hypothyroidism, what symptoms remain despite treatment and whether modifiable factors are continuing to disturb thyroid function.
Sushruta Samhita, Nidana Sthana, Chapter 11, describes Galaganda as a swelling in the neck region associated with disturbance of Vata, Kapha and Meda.[9] Galaganda most closely resembles goitre and should not be treated as an exact synonym for every form of hypothyroidism. Many patients with laboratory confirmed hypothyroidism have no neck swelling.
Charaka Samhita, Chikitsa Sthana, Chapter 15, Grahani Chikitsa, explains the central role of Agni in digestion, assimilation and metabolism.[10] This framework can be clinically useful when a patient has fatigue, constipation, poor appetite, bloating, weight change, cold intolerance, disturbed sleep or reduced exercise capacity.
A personalised Ayurvedic thyroid model
A root directed programme begins by distinguishing autoimmune Hashimoto thyroiditis, iodine imbalance, medicine absorption problems, nutritional deficiencies, post surgical hypothyroidism, thyroid injury, pituitary disease and transient thyroid dysfunction. These conditions do not respond in the same way and should not receive the same formulation.
The Ayurvedic assessment may examine Agni, Ama, Vata, Kapha, Rasa Dhatu, Meda Dhatu, bowel function, sleep, appetite, stress response, menstrual health, weight pattern and exercise tolerance. Modern assessment should continue alongside it, including thyroid stimulating hormone, free T4, free T3 when appropriate, thyroid antibodies, iron status, vitamin B12, vitamin D and other investigations selected according to the clinical history.
The objective is to restore stable digestion, energy, bowel function, sleep, muscle strength and metabolic balance while keeping thyroid hormones within a safe range. In patients with an intact thyroid gland and reversible contributing factors, this approach may help correct factors that continue to worsen symptoms or create unnecessary pressure for repeated dose escalation.
A patient whose thyroid has been completely removed, destroyed by radioactive iodine or permanently damaged may still require lifelong hormone replacement. Ayurveda can support general health and symptom control in such patients, but it cannot manufacture thyroid tissue that is no longer present.
Why self prescribed thyroid herbs may be unsafe during this recall
Patients should not begin a so called thyroid boosting supplement while they may already be receiving excessive thyroid hormone.
A small randomised trial involving 50 adults with subclinical hypothyroidism found that Ashwagandha significantly changed thyroid stimulating hormone, T3 and T4 levels over eight weeks.[7] This finding is sometimes presented as evidence that Ashwagandha supports low thyroid function, but it also shows that the herb can influence thyroid hormone physiology.
A 2024 medical case report described thyrotoxicosis and painless thyroiditis after Ashwagandha use. The patient’s symptoms and thyroid markers improved after the supplement was discontinued.[8] A case report cannot establish how frequently this occurs, but it provides a strong reason for caution when a patient may already be exposed to superpotent thyroid medicine.
Anyone taking Ashwagandha, iodine drops, thyroid glandular supplements or products marketed as metabolism boosters should disclose them to the clinician. Do not start, increase or combine such products during a suspected thyroid hormone excess state without professional review.
Where Ayurveda can provide meaningful value
Ayurveda may be introduced after the affected product has been replaced and the patient is medically stable. The programme can then focus on the underlying disease pattern rather than merely suppressing individual symptoms.
A carefully supervised plan may help improve digestion, constipation, sleep, stress tolerance, muscle strength, healthy weight regulation and quality of life. When autoimmune thyroiditis is present, attention may also be directed toward inflammatory burden, nutritional adequacy, gut health and associated metabolic conditions.
Any future reduction in thyroid hormone should be considered only when repeated laboratory testing and clinical assessment show that the existing dose is no longer required. The decision must be made with the prescribing clinician. Symptom improvement alone is not sufficient evidence to reduce or stop replacement.
This integrated model is more credible than either extreme. It does not ignore the value of essential thyroid hormone, and it does not limit treatment to changing a laboratory number while leaving digestion, sleep, stress, weight and metabolic health unaddressed.
How to Report a Problem to the FDA
Patients who develop an adverse reaction or identify a quality problem can submit a report through the FDA MedWatch programme. Reports may be submitted online or through the MedWatch consumer form.[1]
Before reporting, collect the product name, strength, lot number, expiration date, NDC, dispensing pharmacy, dates of use, symptoms, laboratory results and contact details of the treating clinician.
Patients may also contact Vitruvias Therapeutics at the telephone number or email listed in the FDA recall announcement. Medical symptoms should be discussed with a healthcare provider rather than only reported to the company.
Frequently Asked Questions
What is the recalled thyroid tablet lot number?
The recalled lot number is 504950. It applies to Vitruvias Therapeutics Thyroid Tablets, USP 30 mg with NDC 69680-166-00 and an expiration date of September 30, 2026.[1]
Is the entire Vitruvias thyroid product range recalled?
No. The FDA announcement identifies one lot of the 30 mg strength. Other lots and strengths are not automatically included in this specific recall.[1]
What if my pharmacy bottle does not show a lot number?
Contact the dispensing pharmacy and provide the prescription number, dispensing date, medicine name and strength. The pharmacy may be able to trace the manufacturer lot through inventory and purchase records.
Should I stop taking lot 504950 immediately?
Do not stop without contacting the prescribing clinician. The FDA and company advise patients to obtain guidance and a replacement prescription rather than discontinuing treatment independently.[1]
What are the most important symptoms of superpotent thyroid tablets?
Important symptoms include heat intolerance, sweating, anxiety, tremor, insomnia, weight loss, diarrhoea, muscle weakness, high blood pressure, chest pain, rapid heartbeat and irregular heart rhythm.[1,4,5]
What symptoms require emergency care?
Chest pain, fainting, severe breathlessness, sustained rapid or irregular heartbeat, confusion, high fever, seizure or collapse require emergency assessment.
Is levothyroxine included in this recall?
The recall does not concern all levothyroxine medicines. It concerns one lot of an animal derived thyroid tablet containing both levothyroxine and liothyronine.[1,2]
Can I replace the 30 mg tablet with 30 micrograms of levothyroxine?
No. The doses are not directly equivalent. The recalled 30 mg thyroid tablet contains both T4 and T3, and conversion must be calculated by the prescriber.
Can Ayurveda replace thyroid medicine after this recall?
Ayurveda may support root directed metabolic recovery and address contributing symptoms after the immediate safety issue has been resolved. It should not replace required hormone treatment abruptly. Patients without functioning thyroid tissue generally continue to need replacement.
Is Ashwagandha safe while checking for thyroid hormone excess?
Do not begin or increase Ashwagandha without clinical review. Research indicates that it can alter thyroid hormone levels, and rare cases of thyrotoxicosis have been reported.[7,8]
Final Patient Advice
The FDA thyroid tablet recall 2026 is limited but clinically important. Check for Vitruvias Therapeutics Thyroid Tablets, USP 30 mg, lot 504950, NDC 69680-166-00 and expiration September 30, 2026.
Do not stop the medicine, double a dose or replace it with another thyroid product without professional guidance. Contact the dispensing pharmacy and prescribing clinician promptly. Seek urgent care for rapid or irregular heartbeat, and seek emergency care for chest pain, fainting, severe breathlessness, confusion, seizure or collapse.
Pregnant patients, infants, older adults and people with heart disease require particularly prompt review. Once the recalled product has been replaced and hormone safety is confirmed, an individualised Ayurvedic programme may be considered to support deeper metabolic recovery, digestion, strength, sleep and long term thyroid health.
Medical note: This article is intended for patient education and does not replace individual medical examination, thyroid testing, emergency care or advice from the prescribing clinician.
References
- U.S. Food and Drug Administration. (2026, August 24). Vitruvias Therapeutics, Inc issues nationwide recall of one lot of Thyroid Tablets, USP 30 mg due to potential super potency.
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potential
Used for: Company announcement date, FDA publication date, recalled product, lot number, NDC, expiration date, distribution period, reported units, symptoms, high risk groups, patient advice and adverse event status. (U.S. Food and Drug Administration) - National Library of Medicine. (2024). Thyroid tablet: Vitruvias Therapeutics. DailyMed.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1085f7c-70b3-4850-89c0-5d2b3c6c46cf
Used for: Bottle size, tablet appearance, imprint, labelled T4 and T3 content, available strengths, ingredients and regulatory marketing category. (DailyMed) - U.S. Food and Drug Administration. (2026, August 6). FDA’s actions to address unapproved thyroid medications.
https://www.fda.gov/drugs/enforcement-activities-fda/fdas-actions-address-unapproved-thyroid-medications
Used for: FDA position on animal derived thyroid medicines, approval status, quality concerns, dosing variability and preferred thyroid replacement approach. (U.S. Food and Drug Administration) - American Thyroid Association. (n.d.). Hyperthyroidism. Retrieved August 25, 2026.
https://www.thyroid.org/hyperthyroidism/
Used for: Patient friendly explanation of excess thyroid hormone, heat intolerance, sweating, palpitations, tremor, anxiety, weight loss, bowel changes and sleep disturbance. (American Thyroid Association) - National Library of Medicine. (2025, July 1). Thyroid preparation overdose. MedlinePlus Medical Encyclopedia.
https://medlineplus.gov/ency/article/002592.htm
Used for: Symptoms of excessive thyroid medicine exposure, including anxiety, tremor, insomnia, irregular heartbeat, chest discomfort, vomiting, diarrhoea, seizure and collapse. (MedlinePlus) - Mammen, J. S., McGready, J., Oxman, R., Chia, C. W., Ladenson, P. W., and Simonsick, E. M. (2015). Thyroid hormone therapy and risk of thyrotoxicosis in community resident older adults: Findings from the Baltimore Longitudinal Study of Aging. Thyroid, 25(9), 979 to 986.
https://pubmed.ncbi.nlm.nih.gov/26177259/
Used for: Evidence concerning thyroid hormone overtreatment, iatrogenic thyrotoxicosis, atrial fibrillation and reduced bone density in older adults. (PubMed) - Sharma, A. K., Basu, I., and Singh, S. (2018). Efficacy and safety of Ashwagandha root extract in subclinical hypothyroid patients: A double blind, randomised placebo controlled trial. Journal of Alternative and Complementary Medicine, 24(3), 243 to 248.
https://pubmed.ncbi.nlm.nih.gov/28829155/
Used for: The small human trial showing significant changes in thyroid stimulating hormone, T3 and T4 after eight weeks of Ashwagandha use. (PubMed) - Hayashi, M., Hamada, H., Azuma, S., and Hayashi, K. (2024). Painless thyroiditis by Withania somnifera, Ashwagandha. Cureus, 16(3), e55352.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10981964/
Used for: Medical case report of thyrotoxicosis and painless thyroiditis following Ashwagandha use, with improvement after discontinuation. (PubMed Central (PMC)) - Sushruta. (n.d.). Diagnosis of glands, scrofula, tumours and goitre. In Sushruta Samhita, Nidana Sthana, Chapter 11. K. L. Bhishagratna, Translator.
https://www.wisdomlib.org/hinduism/book/sushruta-samhita-volume-2-nidanasthana/d/doc142869.html
Used for: Classical description of Galaganda and the involvement of Vata, Kapha, Meda and the neck region. (Wisdom Library) - Charaka Samhita Research, Training and Skill Development Centre. (2025). Grahani Chikitsa: Management of diseases of digestion and metabolism. Charaka Samhita, Chikitsa Sthana, Chapter 15.
https://www.carakasamhitaonline.com/index.php/Grahani_Chikitsa
Used for: Classical Ayurvedic principles concerning Agni, digestion, assimilation, tissue nourishment and metabolic balance. (Caraka Samhita Online)
